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Abstract To explore peptide hormone-induced conformational
changes, we attempted to engineer a metal^ion binding site
between the cytoplasmic loops CD and EF in the angiotensin II
type 1 (AT1) receptor. We constructed 12 double and six triple
histidine mutant receptors, and tested the ability of each mutant
and the wild-type to activate inositol phosphate (IP) production
with and without ZnCl2. Inhibition by ZnCl2 in the double and
triple His mutant receptors was not significant, but these
mutations directly decreased the IP production. Systematic
analysis of single His mutants demonstrated that the loop CD-
mutants displayed 52^74% inhibition of IP production, whereas
the loop EF-mutants did not affect IP production. These results
indicate that the cytoplasmic loop CD-segment from Tyr127 to
Ile130 is important for Gq=11 activation by the AT1 receptor.
z 2000 Federation of European Biochemical Societies.
Key words: Angiotensin II; G protein coupling;
metal^ion binding site; Peptide hormone receptor activation;
CD-loop; EF-loop
1. Introduction
The octapeptide hormone angiotensin II (Ang II) is an im-
portant regulator of blood pressure, water^electrolyte balance
and is an important growth factor for many cell types. Ang II
type 1 receptor (AT1) is necessary and su⁄cient for regulating
most of the known functions attributed to Ang II. The AT1
receptor contains a seven transmembrane helical structural
motif which is common to members of the G protein coupled
receptor (GPCR) superfamily. It activates intracellular inosi-
tol phosphate (IP) production via coupling to pertussis toxin-
insensitive G protein Gq=11 [1]. The Ang II binding pocket
consists of the transmembrane domain and extracellular
loops. We have previously reported two salt-bridge interac-
tions which are important for Ang II docking to the receptor
and that the interactions of the Tyr4 and Phe8 residues of Ang
II initiate the AT1 receptor activation process [2^6]. However,
the receptor-G protein interaction sites are poorly understood.
Because the knowledge of the molecular structure of the
vast majority of GPCRs is not currently available, indirect
experimental methods are currently employed to deduce the
structure function relation. A homology model developed by
Baldwin [7] and the low resolution structure of visual rhodop-
sin currently being characterized form the basis for models
that can be built for the AT1 receptor as well as other
GPCR membrane proteins [8]. Mutational analysis suggests
that key elements involved in Ang II binding and the receptor
activation process are similar to many di¡erent GPCRs, sug-
gesting that GPCRs may adopt a similar conformation.
Therefore, crucial tertiary interactions determined within the
G protein binding site for one receptor should be reproducible
in another receptor. In one study Thistrup et al. [9] were able
to transfer an engineered metal^ion binding site from the
NK1 receptor to the U-opioid receptor demonstrating conser-
vation of the local structure [9,10]. Metal^ion binding sites are
suitable for such analysis because the structures of naturally
occurring metal binding sites are known and similar sites have
been built into other model proteins [11]. These sites are small
and geometrically precise interactions required for binding
metal ions provide important information regarding the spa-
tial orientation and proximity of amino acids involved [9^12].
Participation of CD- and of EF-loops (also called intracel-
lular loops 2 and 3, respectively) of GPCRs in G protein
selection and signal activation is known [13^15]. In addition,
mutagenesis, spectroscopy and site-directed spin labeling stud-
ies in rhodopsin, a well characterized GPCR, point to motion
of TM helices C, F and G as a key element in transmitting
signal to the cytoplasmic domain of the receptor [16^19]. The
TM helices C and F are in close proximity and are a part of
the binding site for the retinal G protein, transducin and
suggest that movements of these helices relative to one anoth-
er are required for transducin activation [20]. Recently, Sheikh
et al. [21] demonstrated that a Zn binding site engineered
between TM helices C and F in bovine rhodopsin by intro-
duction of His residues at predetermined sites blocked trans-
ducin activation by light-activated rhodopsin. In the present
study we attempted to move this well de¢ned zinc binding site
to the Gq=11 coupled, peptide hormone receptor, AT1, which
bears only 30% identity with bovine rhodopsin in the TM
domain.
2. Materials and methods
2.1. Materials
[Sar1]Ang II was purchased from Bachem. 125I-[Sar1,Ile8]Ang II was
purchased from The Peptide Radioiodination Center of Washington
State University, Pullman, WA. The speci¢c activity of the 125I-
[Sar1,Ile8]Ang II was 2200 Ci/mmol. Losartan was a gift from DuPont
Merck, Wilmington, DE.
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2.2. Mutagenesis and expression of the AT1 receptor
The synthetic rat AT1 receptor gene, cloned in the shuttle expres-
sion vector pMT-3, was used for expression and mutagenesis, as de-
scribed earlier [5,6]. Mutants were prepared by Altered Sites0 II in
vitro mutagenesis system according to the manufacturer’s instructions
(Promega, Madison, WI). The DNA sequence analysis was done to
con¢rm the mutations. To express the AT1 receptor protein, 10 Wg of
puri¢ed plasmid DNA/107 cells was used in transfection. COS1 cells
(American type culture collection, Rockville, MD) cultured in Dul-
becco’s modi¢ed minimal essential medium (DMEM) supplemented
with 10% fetal bovine serum, were transfected by the DEAE-dextran
method. Transfected cells cultured for 72 h were harvested and cell
membranes were prepared by the nitrogen parbomb disruption meth-
od. The receptor expression was assessed in each case by immunoblot
analysis (not shown) and by 125I-[Sar1,Ile8]Ang II saturation binding
analysis.
2.3. Radioligand binding studies
125I-[Sar1,Ile8]Ang II binding experiments were carried out under
equilibrium conditions, as described earlier [5,6]. For competition
binding studies, membranes expressing the wild-type (WT) receptor
or the mutants were incubated at room temperature for 1 h with 300
pM 125I-[Sar1,Ile8]Ang II and various concentrations of the agonist or
antagonist. All binding experiments were carried out at 22‡C in a 250
Wl volume. Non-speci¢c binding of the radioligand was measured in
the presence of 1 mM 127I-[Sar1,Ile8]Ang II. After equilibrium was
reached, the binding experiments were stopped by ¢ltering the binding
mixture through Whatman GF/C glass ¢ber ¢lters, which were exten-
sively washed further with binding bu¡er to wash the free radioligand.
The bound ligand fraction was determined from the counts per minute
(CPM) remaining on the membrane. Equilibrium binding kinetics
were determined using the computer program Ligand0. The Kd values
represent the mean þ S.E.M. of three to ¢ve independent determina-
tions.
2.4. IP formation studies
Semi-con£uent COS1 cells transfected in 60 mm petri dishes were
labeled for 24 h with [3H]myo-inositol (1.5 WCi/ml), speci¢c activity
22 mCi/mol (Amersham), at 37‡C in DMEM containing 10% bovine
calf serum. On the day of the functional assay, the labeled cells were
washed with HBSS three times and incubated with HBSS containing
10 mM LiCl for 20 min. 10 WM [Sar1]Ang II, the AT1 receptor agonist
was added and incubated for another 45 min at 37‡C. In zinc metal^
ion binding experiments, we preincubated with or without 20 mM
ZnCl2 for 2 h before washing. 20 mM ZnCl2 was maintained through-
out the IP production assay. At the end of incubation, the medium
was removed, and total soluble IP was extracted from the cells by the
perchloric acid extraction method, as described previously. The
amount of [3H]IP eluted from the column was counted and a concen-
tration response curve was generated using iterative non-linear regres-
sion analysis (see [5,6]). Results expressed as percentage of IP pro-
duced assuming that [Sar1]Ang II stimulated maximal function.
2.5. Statistical analysis
The results are expressed as the mean þ S.E.M. of two to ¢ve in-
dependent determinations. The signi¢cance di¡erences in measured
values were evaluated with an unpaired Student’s t-test. Statistical
signi¢cance was set at a level of P6 0.05.
3. Results
3.1. Substitution of histidine residues in the proposed
interaction site for Gq=11
The cytoplasmic loops CD and EF participate in the bind-
ing sites for the G protein. Fig. 1 shows alignment of CD and
EF loop sequences of the AT1 receptor and bovine rhodopsin.
Anchoring the highly conserved DRY sequence indicated that
Ala129 and His132 in the CD loop of AT1 receptor correspond
to Val138 and Lys141 of the bovine rhodopsin. These residues
along with Thr251 in the EF loop in rhodopsin formed a Zn
binding site when substituted with His [21]. Phe239 in the EF-
loop of the AT1 receptor corresponds to Thr251 of rhodopsin.
To examine whether the topological arrangement of these
residues is conserved between these two GPCRs, we mutated
the residues in the AT1 receptor that correspond to the rho-
dopsin residues mentioned above. We constructed a triple
histidine (A129H/H132/F239H) mutant receptor as a ¢rst
step for engineering a metal^ion binding site in the Gq-inter-
action site on the AT1 receptor, since these residues have been
shown to form a Zn binding site in bovine rhodopsin. To
extend the mapping study further relevant segments of CD
and EF loops were mutagenized. This led to an additional
¢ve triple His mutant and 12 double His mutants. These mu-
tants were expressed in COS1 cells, and the expression was
measured by immunoblotting (data not shown) and their
function was measured by IP-formation (Fig. 1).
3.2. Zinc did not a¡ect IP production in double His and triple
His mutant receptors
WT (single histidine, His132), double and triple histidine
mutants transiently transfected in COS1 cells yielded compa-
rable levels of cell surface receptors that bound the agonist
[Sar1]Ang II, and the antagonist Dup753 with high a⁄nity.
[Sar1]Ang II stimulated a W20-fold increase in IP formation
in the WT AT1 receptor (Fig. 2A). This stimulation was not
signi¢cantly a¡ected by 1^20 mM ZnCl2 (concentration that
inhibited transducin activation by rhodopsin mutants in the
same cell system [21]). ZnCl2 alone did not activate IP for-
mation in AT1 receptor transfected COS1 cells. All of the
double and triple histidine mutants activated IP-formation
at signi¢cantly reduced levels (inhibition was 70 and 59%,
respectively) when stimulated with [Sar1]Ang II. Presence of
ZnCl2 did not alter the levels of IP produced in double and
triple histidine mutants (2 and 10% reduced, respectively, see
Fig. 2A,B) under several di¡erent concentrations of ZnCl2.
3.3. Mutations A129H and A129H/H132Q but not F239H
alter IP production
To identify the mutation that actually caused the ZnCl2-
Fig. 1. A secondary structure model of the 359-residue rat AT1 re-
ceptor (AT1R). The transmembrane segments are putative K-helices
forming the ligand pocket. The residues 125^143 of cytoplasmic
loop CD and 223^240 of loop EF of rat AT1 receptor (AT1R)
aligned with the corresponding regions of bovine rhodopsin (Rho)
(134^151 of loop CD and 231^252 of loop EF is Rho residue num-
bering) are shown.
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independent inhibition of IP production, we directly com-
pared A129H, A129H/H132Q and F239H mutant receptors
for the ability to bind ligands and stimulate IP production
in COS cells. The a⁄nity of the mutant receptors for
[Sar1]Ang II and Dup753 were similar to that of the WT
receptor (Table 1). Inhibition of IP production in the mutant
A129H was 52% and was further increased (63%) in the
A129H/H132Q mutant receptor (Fig. 2C). The F239H muta-
tion did not a¡ect IP production (Fig. 2B).
3.4. The CD-loop region in the AT1 receptor is essential for
e⁄cient IP formation
To further de¢ne the regions that are important for cou-
pling to IP production, we constructed additional mutants ^
Y127H, L128H, I130H in the CD-loop and R234H, N235H,
D236H, D237H, R240H in the EF-loop ^ in addition to
A129H and F239H. Kd of [Sar1]Ang II and Dup753 and
Bmax in these mutant receptors were comparable to that of
the WT receptor (Table 1). The IP production stimulated by
the CD-loop mutants was 52^74% lower compared to the WT
(Fig. 2C). The EF-loop mutations (that retain His132, hence
are double His mutants) did not a¡ect IP production (Fig.
2B).
4. Discussion
The main ¢nding in this study is the identi¢cation of the
cytoplasmic CD-loop segment in AT1 receptor as an impor-
tant region for e⁄ciently coupling the hormone binding signal
Fig. 2. Basal and [Sar1]Ang II-stimulated (10 WM) maximal IP pro-
duction stimulated by the WT and mutant AT1 receptors pretreated
with or without 20 mM ZnCl2. Basal stimulation of IP accumula-
tion was measured in mock transfected cells (W1800 þ 150 cpm/107
cells) and adjusted to 0%. The [Sar1]Ang II-stimulated IP accumula-
tion for all mutants shown was calculated considering the stimula-
tion by the WT AT1 receptor as 100% of (12 000 þ 500 cpm/107
cells). Expression level of each of the mutants was measured by im-
munoblot analysis. This semi-quantitative method, which is sensitive
to measure s two-fold changes in receptor level, indicated that cell
surface receptor densities were not signi¢cantly di¡erent between
di¡erent mutants examined in this study. Results shown are the
mean þ S.E.M. of three independent determinations. *P6 0.05 vs.
[Sar1]Ang II on WT.
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Table 1
Ligand a⁄nities of WT and mutant AT1 receptors expressed in COS cells
Bmax (pmol/mg protein) Kd (nM)
[Sar1]Ang II Dup753
WT (single, H132) 4.3 þ 0.3 0.31 þ 0.02 17 þ 1
A129H/H132Q/F239H (double) 3.7 þ 0.6 1.05 þ 0.09 26 þ 1
A129H/H132/F239H (triple) 4.6 þ 0.6 1.15 þ 0.26 21 þ 9
A129H/H132Q 4.1 þ 0.2 0.49 þ 0.15 20 þ 4
Y127H 3.5 þ 0.1 0.32 þ 0.02 16 þ 3
L128H 5.6 þ 0.2 0.35 þ 0.06 16 þ 2
A129H 5.4 þ 0.2 0.34 þ 0.03 23 þ 7
I130H 4.0 þ 0.2 0.42 þ 0.01 20 þ 7
R234H 3.8 þ 0.2 0.31 þ 0.05 17 þ 1
N235H 3.0 þ 0.2 0.48 þ 0.10 19 þ 1
D236H 4.5 þ 0.4 0.83 þ 0.13 12 þ 2
D237H 5.1 þ 0.1 1.18 þ 0.30 15 þ 3
F239H 4.3 þ 0.6 0.94 þ 0.24 25 þ 4
R240H 3.7 þ 0.1 0.91 þ 0.03 17 þ 5
The Bmax and Kd values represent the mean þ S.E.M. obtained from two of four independent transfection experiments performed in duplicate.
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to the activation of Gq=11 protein leading to IP formation.
Substitution of each residue in this segment caused the defect,
indicating low tolerance for structural changes. This con-
straint signi¢cantly restricted our attempts to engineer a Zn
binding site between the CD-loop and EF-loop. Previously,
Ohyama et al. have indicated that the DRY and KSR se-
quence motifs in the CD-loop are important functions [22].
However, subsequent studies shifted the focus to the function-
al signi¢cance of membrane proximal regions of C-tail and
EF-loop [23,24] in the AT1 receptor. The possibility that the
observed defect is because of the His residue substituted in-
stead of isosteric residues in each case cannot be ruled out.
But since His substitution at several positions in the EF-loop
did not induce similar defects, this explanation appeared un-
likely to us. Ridge et al. [17] substituted Cys residues in the
CD-loop of bovine rhodopsin to map residues that are critical
for transducin activation. Their results indicated that each of
the residue between the conserved Glu134Arg135 sequence and
Pro142 inhibited W70% of transducin activation (see Fig. 1 for
comparison). Yang et al. [25] used an identical approach to
study the EF-loop residues in rhodopsin and found that
the region between Lys245 and Arg252 when mutated retained
s 80% transducin activation. These observations in rhodopsin
are replicated in this study for the AT1 receptor (Fig. 2).
Several di¡erent GPCRs have been shown to have an active
involvement of loop CD for G protein coupling and of loop
EF for signal activation [13^15]. Kobilka et al. [14] suggested
that with chimeric K2- and L2-adrenergic receptors, the specif-
icity for coupling to the G protein is within loop EF. Kubo et
al. [15] concluded that in the muscarinic acetylcholine recep-
tor, the selective coupling of M1 and M2 subtypes with di¡er-
ent e¡ector systems is due to the loop EF region in these
receptors. Wong et al. [26] indicated with chimeric muscarinic
acetylcholine/L-adrenergic receptors that the third cytoplasmic
loop determines G protein speci¢city of the receptor. Conser-
vation of these features in the cytoplasmic loops in conjunc-
tion with structural and functional features in the TM helices
C and F in nearly every GPCR characterized to date has led
to a proposed mechanism of signal transduction that is com-
mon to all GPCRs [27]. The mechanism predicts rigid body
movement of TM helices (C, F and G) inducing conforma-
tional changes in the cytoplasmic loops that induce G protein
activation by the receptor in response to agonist [27]. How
segments on the cytoplasmic domain of di¡erent GPCRs in-
teract to select a speci¢c G protein from a pool of structurally
similar G proteins remains an intense area of current research.
Tertiary interaction of residues in the cytoplasmic domain
of bovine rhodopsin is beginning to be elucidated. Recently
Farrens et al. [28] demonstrated that Cys139 (in the CD-loop)
could be induced to form a disul¢de link with a Cys residue
introduced at several positions in the EF-loop, indicating their
proximity. Engineering of a metal^ion binding site to demon-
strate Zn-dependent restrain of activation-induced conforma-
tional change in the Sheikh et al. [21] study is an elegant
independent con¢rmation of the proposed spatial proximity
of CD and EF loop regions in rhodopsin. We attempted to
move this well de¢ned zinc binding site in the present study to
the Gq coupled peptide hormone receptor, AT1 receptor, to
demonstrate that geometry of crucial residues for function is
similar to that in rhodopsin. The sequence alignments indi-
cated that the AT1 receptor segments examined here corre-
spond to the CD- and EF-loop regions of bovine rhodopsin
(Fig. 1). E¡ect on IP formation of mutations in these two
segments recapitulate the phenotype in rhodopsin indicating
that these segments are functionally equivalent to the seg-
ments in rhodopsin. Therefore, we anticipated spatial proxim-
ity of residues, Ala129, His132 and Phe239. We chose these
residues for substitution with His in di¡erent combinations
to create a potential metal^ion binding site. In the presence
or absence of ZnCl2 we tested the ability of each of the mu-
tants to activate IP production in COS cells. The results show
that Zn did not block IP formation stimulated by these mu-
tants (Fig. 2A). Whether the lack of Zn-inhibition is because
of the G protein di¡erences or it indicates di¡erences in the
geometry of CD-loop interaction with the EF-loop is unclear.
This result is especially important since it is the ¢rst report of
an attempt to engineer a metal^ion binding site in the G
protein binding domain of a hormone receptor. Furthermore,
the lack of e¡ect by ZnCl2 may suggest subtle conformational
variability between the two receptors compared. The possibil-
ity that such di¡erences may be important to distinguish dif-
ferent classes of G proteins (Gq=11 vs. Gt) needs further study
of speci¢c conformation in the AT1 as well as other GPCRs.
This will be the focus of our future studies.
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